Andera Partners — 13F Holdings & Portfolio
CIK 1757283 · latest 13F-HR filed 2026-05-11
Andera Partners manages $176.9M in 13F-reported U.S. long-equity assets across 7 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are KMTS (30.36%), EVMN (24.66%), MLYS (24.38%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 2 new positions, exited 0, added to 2, and trimmed 3.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$176.9M
Long-equity book
7
Distinct positions
2026-03-31
Filed 2026-05-11
+2 / −0 / ↑2 / ↓3
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Trims
- MINERALYS THERAPEUTICS INC-$14.6M -25.4%
- KESTRA MED TECHNOLOGIES LTD-$13.6M -20.3%
- ABIVAX SA-$1.8M -17.4%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | KESTRA MED TECHNOLOGIES LTD | KMTS | G52441105 | $53.7M | 30.36% | 2,695,192 | SH |
| 2 | EVOMMUNE INC | EVMN | 30054Y107 | $43.6M | 24.66% | 1,897,362 | SH |
| 3 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $43.1M | 24.38% | 1,591,917 | SH |
| 4 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $16.1M | 9.12% | 1,538,702 | SH |
| 5 | INVENTIVA SA | IVA | 46124U107 | $10.1M | 5.70% | 1,818,181 | SH |
| 6 | ABIVAX SA | ABVX | 00370M103 | $8.7M | 4.92% | 78,125 | SH |
| 7 | NYXOAH S A | NYXH | B6S7WD106 | $1.5M | 0.86% | 522,057 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | $176.9M | 7 | 0001757283-26-000012 |
| 2025-12-31 | 2026-02-17 | $176.6M | 5 | 0001757283-26-000007 |